
Stem cell bank LifeCell raises ₹225 crore
The Hindu
The additional funds would enable LifeCell to make a foray into adjacent new categories such as fertility health and cell-based therapeutics.
Stem cell bank and reproductive genetic testing service provider LifeCell International Pvt. Ltd. said that OrbiMed Asia Partners IV has invested ₹225 crore in return for a minority stake.
“We received an equity infusion of ₹225 crore from leading healthcare investment firm OrbiMed Asia Partners IV. The existing founders will invest ₹30 crore,” said Mayur Abhaya, MD.
The additional funds would enable LifeCell to make a foray into adjacent new categories such as fertility health and cell-based therapeutics. Besides, it would also enable the company grow its diagnostic division and set up laboratories offering varied kinds of tests.

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












